Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
Financials
Financial year 2025
MONA LISA from Herk-de-Stad, company number BE0456182981, closed financial year 2025 with a result of € -83,430 after tax. For that financial year MONA LISA recorded revenue of € 4.2 million and equity of € 2 million. Compared with financial year 2024, the result moved from € -591,361 to € -83,430. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 29, 2026.
€ 2 million
▼ 4% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -83,430
▲ 86 % less loss than in 2024
Profit after tax over the fiscal year.
€ 825,883
▼ 42% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 1.9 million.
People and assets in 2025
9.7
▲ 0.3 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 744,547
▲ 29% vs 2024
€ 76,800 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 12,150
▼ 19% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 374,418
▼ 66% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 124,911
▼ 8% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 3,097,897 | € 3,439,473 | € 3,074,288 | € 4,187,685 | ▲ 36% |
| Gross margin | - | - | € 89,734 | € 663,565 | ▲ € 573,831 |
| Profit after taxes | € 363,630 | € 280,820 | € -591,361 | € -83,430 | ▲ € 507,932 |
| Equity | € 2,411,383 | € 2,692,204 | € 2,100,842 | € 2,017,412 | ▼ 4% |
| Total debts | € 794,204 | € 666,673 | € 1,275,469 | € 537,655 | ▼ 58% |
| Cash | € 1,288,920 | € 1,621,238 | € 1,435,592 | € 825,883 | ▼ 42% |
| Land & buildings | € 638,609 | € 614,475 | € 628,093 | € 603,038 | ▼ 4% |
| Retained profit | € 2,341,383 | € 2,622,204 | € 2,030,842 | € 1,947,412 | ▼ 4% |
| Balance sheet total | € 3,205,587 | € 3,358,877 | € 3,376,311 | € 2,555,067 | ▼ 24% |
| Employees (FTE) | 4.4 | 7.4 | 9.4 | 9.7 | ▲ 0.3 |
Key figures of MONA LISA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to MONA LISA?
What happened at MONA LISA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- EurimPharm Vertriebs Gmbh & Co Kg stepped down as director. NBB
- Magdalena Hrubesch stepped down as director. NBB
- Alphamed Arzneimittel Gmbh & Co Kg stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 83,430. Source: NBB ↗
- EurimPharm Vertriebs Gmbh & Co Kg became a director. NBB
- Magdalena Hrubesch became a director. NBB
- Alphamed Arzneimittel Gmbh & Co Kg became a director. NBB
- New establishment in Herk-de-Stad. KBO
In short
From € 363,630 profit in 2022 to € 83,430 loss in 2025.
Paid € 234,247 in corporate taxes since 2022.
Best year ever: 2022, with € 363,630 profit.
On average € 68,400 of value added per employee in 2025.
A new publication or filing at MONA LISA? We notify you, reason included.
Follow MONA LISADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by Friederike Dr. Hrubesch-Mohringer and Alphamed Arzneimittel Gmbh & Co Kg.
Directors
According to the 2025 annual accounts
EurimPharm Vertriebs Gmbh & Co Kg
Director · represented by Wolfgang Stallmayer
since 2025 · until 2032
Magdalena Hrubesch
Director
since 2025 · until 2032
Alphamed Arzneimittel Gmbh & Co Kg
Managing director · represented by Friederike Dr. Hrubesch-Mohringer
since 2025 · until 2032
Shareholders
Friederike Dr. Hrubesch-Mohringer
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Kapelstraat 1
3540 Herk-de-Stad
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0456.182.981
- VAT number
- BE 0456.182.981
- Registered office
- Kapelstraat 1, 3540 Herk-de-Stad
- Names & denominations
- MONA LISA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 2 October 1995
- Peppol
- Active · Active since 19 Aug 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten
Vervaardiging van medische en tandheelkundige instrumenten en benodigdheden
Vervaardiging van niet-elektrische apparaten en instrumenten voor de geneeskunde, de tandheelkunde en de veeartsenijkunde